AtriCure, Inc. 10-Q Summary: Quarter Ended March 31, 2008
Business Context and Reporting Period
AtriCure, Inc. is a medical device company focused on the surgical treatment of atrial fibrillation (AF). The company develops, manufactures, and sells cardiac ablation products, primarily the Isolator bipolar ablation system, to hospitals and medical centers in the United States and internationally. This report covers the quarterly period ended March 31, 2008.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Revenues | $13,530,145 | $10,750,770 |
| Gross Profit | $10,299,265 | $8,540,275 |
| Gross Margin | 76.1% | 79.4% |
| Net Loss | $(3,605,435) | $(4,302,421) |
| Loss Per Share (Basic/Diluted) | $(0.25) | $(0.35) |
| Cash and Cash Equivalents | $13,014,579 | $13,186,141 |
| Short-Term Investments | $1,903,904 | $7,006,041 |
| Total Debt (Current + Long-Term) | $686,755 | $1,107,621 |
| Working Capital | $21,530,973 | $24,623,721 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 25.9% year-over-year, driven by a 21% increase in unit sales, a 4% increase in average selling prices, and a 1% benefit from currency exchange rates.
- Margin Compression: Gross margin decreased from 79.4% to 76.1%. This was primarily due to the introduction and sale of the ORLab system, which carries a higher cost of revenue than the company's disposable products.
- Operating Expenses: Total operating expenses increased to $14.2 million from $13.4 million. Selling, general, and administrative (SG&A) expenses rose $1.5 million due to increased headcount in sales. Conversely, Research and Development (R&D) expenses decreased $0.7 million due to the redeployment of staff from clinical activities to sales.
- Net Loss Improvement: The net loss narrowed by approximately $0.7 million compared to the prior year, despite higher operating expenses, due to significant revenue growth.
- Investment Portfolio: Short-term investments decreased significantly from $7.0 million to $1.9 million as the company matured $5.1 million in securities during the quarter.
Guidance, Outlook, and Risks
- Product Pipeline: The company introduced the ORLab mapping system and the Coolrail linear ablation device in Q1 2008. A new disposable cryoablation probe is planned for release in the second half of 2008.
- Regulatory Status: While products are FDA-cleared for cardiac tissue ablation, they are not yet cleared specifically for the treatment of AF. The company is conducting the ABLATE clinical trial to seek FDA approval for AF treatment, with a potential approval target of 2010.
- Liquidity: Management believes current cash and cash equivalents ($14.9 million including short-term investments) are sufficient to meet needs for at least the next 12 months. The company maintains a $5.0 million credit facility with $0.6 million outstanding.
- Legal Proceedings: The company is a defendant in a securities class action lawsuit (Levine v. AtriCure, Inc.) alleging violations of federal securities laws regarding its 2005 IPO. The company intends to vigorously defend against the claims.
- Seasonality: The company typically experiences a sequential revenue decline in the third quarter due to the elective nature of cardiac procedures during summer months.
Investor Verification Checklist
- Verify the timeline and progress of the ABLATE clinical trial and the potential 2010 FDA approval for AF treatment.
- Monitor the adoption rate and cost structure of the new ORLab and Coolrail products to assess future gross margin trends.
- Review the status of the pending securities class action lawsuit and any potential financial impact.
- Assess the company's cash burn rate relative to its current liquidity position to determine the need for future capital raises.
- Confirm the status of the left atrial appendage exclusion system clinical evaluation in Europe and its U.S. regulatory pathway.